DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

11 Mar 2021 08:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

25 Feb 2021 16:01:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

12 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

05 Feb 2021 09:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

11 Jan 2021 08:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

08 Jan 2021 08:30:00 By Nasdaq GlobeNewswire